Skip to main content
OpenTrials

Clinical trial condition

Hepatitis C

Explore clinical trials studying Hepatitis C. Study availability and eligibility vary by location and protocol.

449 public trials 3 recruiting studies
Refine in advanced search Browse all conditions

Hepatitis C trial results

Completed

A Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 on Combination Treatment With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)

NCT01447420

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • Vitória, Espírito Santo, Brazil
  • Salvador, Estado de Bahia, Brazil
  • Juiz de Fora, Minas Gerais, Brazil
  • Rio de Janeiro, Brazil
View all 15 locations
View Trial Details
Completed

Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).

NCT00087607

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • Birmingham, Alabama, United States
  • Little Rock, Arkansas, United States
  • Sacramento, California, United States
  • San Diego, California, United States
View all 41 locations
View Trial Details
Completed

Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.

NCT00107653

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • Scottsdale, Arizona, United States
  • Tucson, Arizona, United States
  • Anaheim, California, United States
  • Fountain Valley, California, United States
View all 60 locations
View Trial Details
Completed

POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin).

NCT00700401

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • Vitória, Espírito Santo, Brazil
  • Brasília, Federal District, Brazil
  • São Luís, Maranhão, Brazil
  • Rio de Janeiro, Brazil
View Trial Details
Completed

Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients

NCT01525628

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • 1241.27.0006 Boehringer Ingelheim Investigational Site La Mesa, California, United States
  • 1241.27.0005 Boehringer Ingelheim Investigational Site Rockville, Maryland, United States
  • 1241.27.0004 Boehringer Ingelheim Investigational Site Marlton, New Jersey, United States
  • 1241.27.0003 Boehringer Ingelheim Investigational Site Philadelphia, Pennsylvania, United States
View all 16 locations
View Trial Details
Completed

A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + Ribavirin

NCT00087568

Conditions
Blood-Borne Infections, Chronic Disease, Communicable Diseases, +14 more
Locations
  • Bakersfield, California, United States
  • Pasadena, California, United States
  • San Diego, California, United States
  • San Mateo, California, United States
View all 25 locations
View Trial Details

Related conditions